Do analysts prefer LNAI or ALBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Avalon GloboCare N/A N/A -74.36%

Do analysts prefer ALBT or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALBT or COCP more profitable?

Avalon GloboCare's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Cocrystal Pharma N/A -150.61% -97.86%

Does the media favor ALBT or COCP?

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 0.96 beat Cocrystal Pharma's score of 0.93 indicating that Avalon GloboCare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ALBT or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ALBT or BLRX?

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. BioLineRx's average media sentiment score of 1.27 beat Avalon GloboCare's score of 0.96 indicating that BioLineRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLineRx 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BIVI or ALBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIVI or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Avalon GloboCare N/A N/A -74.36%

Does the media prefer BIVI or ALBT?

In the previous week, BioVie and BioVie both had 1 articles in the media. BioVie's average media sentiment score of 1.89 beat Avalon GloboCare's score of 0.96 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALBT or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALBT or QNTM more profitable?

Avalon GloboCare's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Quantum Biopharma N/A -941.54% -224.41%

Does the media refer more to ALBT or QNTM?

In the previous week, Quantum Biopharma had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.96 beat Quantum Biopharma's score of 0.52 indicating that Avalon GloboCare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avalon GloboCare (ALBT) Competitors

$0.29 -0.02 (-5.84%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$0.30 +0.01 (+2.41%)

As of 07/17/2026 07:43 PM Eastern

Compare

ALBT vs. LNAI, COCP, BLRX, BIVI, and QNTM

Should you buy Avalon GloboCare stock or one of its competitors? MarketBeat compares Avalon GloboCare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalon GloboCare include Lunai Bioworks (LNAI), Cocrystal Pharma (COCP), BioLineRx (BLRX), BioVie (BIVI), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry.

How does Avalon GloboCare compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Lunai Bioworks has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Avalon GloboCare has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Avalon GloboCare	$1.26M	3.34	-$18.26M	-$3.51	N/A

In the previous week, Avalon GloboCare had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.43 beat Avalon GloboCare's score of 0.96 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Avalon GloboCare	Positive

Avalon GloboCare's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Avalon GloboCare	N/A	N/A	-74.36%

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Avalon GloboCare beats Lunai Bioworks on 7 of the 11 factors compared between the two stocks.

How does Avalon GloboCare compare to Cocrystal Pharma?

Avalon GloboCare (NASDAQ:ALBT) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 0.96 beat Cocrystal Pharma's score of 0.93 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalon GloboCare's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Avalon GloboCare has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Cocrystal Pharma has lower revenue, but higher earnings than Avalon GloboCare. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	3.34	-$18.26M	-$3.51	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Avalon GloboCare and Cocrystal Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Avalon GloboCare compare to BioLineRx?

Avalon GloboCare (NASDAQ:ALBT) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Avalon GloboCare has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Avalon GloboCare's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
BioLineRx	-563.70%	-37.73%	-19.42%

BioLineRx has lower revenue, but higher earnings than Avalon GloboCare. BioLineRx is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	3.34	-$18.26M	-$3.51	N/A
BioLineRx	$1.18M	10.74	-$1.17M	-$1.92	N/A

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalon GloboCare has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. BioLineRx's average media sentiment score of 1.27 beat Avalon GloboCare's score of 0.96 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLineRx	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLineRx beats Avalon GloboCare on 7 of the 12 factors compared between the two stocks.

How does Avalon GloboCare compare to BioVie?

BioVie (NASDAQ:BIVI) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

BioVie has higher earnings, but lower revenue than Avalon GloboCare. BioVie is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Avalon GloboCare	$1.26M	3.34	-$18.26M	-$3.51	N/A

4.6% of BioVie shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BioVie and BioVie both had 1 articles in the media. BioVie's average media sentiment score of 1.89 beat Avalon GloboCare's score of 0.96 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioVie has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Avalon GloboCare's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Avalon GloboCare	N/A	N/A	-74.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioVie and Avalon GloboCare tied by winning 5 of the 10 factors compared between the two stocks.

How does Avalon GloboCare compare to Quantum Biopharma?

Avalon GloboCare (NASDAQ:ALBT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Avalon GloboCare has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	3.34	-$18.26M	-$3.51	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

In the previous week, Quantum Biopharma had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.96 beat Quantum Biopharma's score of 0.52 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalon GloboCare's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Quantum Biopharma	N/A	-941.54%	-224.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avalon GloboCare has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Summary

Avalon GloboCare beats Quantum Biopharma on 9 of the 11 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALBT vs. The Competition

Export

Metric	Avalon GloboCare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.47M	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-0.08	20.85	27.14	23.89
Price / Sales	3.34	304.43	524.02	90.49
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	-0.08	8.26	10.69	6.18
Net Income	-$18.26M	$23.83M	$3.59B	$331.73M
7 Day Performance	4.43%	-3.48%	-2.18%	-2.04%
1 Month Performance	-14.71%	2.58%	1.63%	-2.14%
1 Year Performance	-86.57%	45.93%	25.56%	17.28%

Avalon GloboCare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALBT Avalon GloboCare	0.7177 of 5 stars	$0.29 -5.8%	N/A	-87.7%	$4.47M	$1.26M	N/A	5	Short Interest Decrease Gap Down
LNAI Lunai Bioworks	0.7899 of 5 stars	$2.96 -0.7%	N/A	N/A	$13.41M	$20.94K	N/A	20	Positive News Short Interest Decrease
COCP Cocrystal Pharma	0.5863 of 5 stars	$0.97 +2.9%	N/A	-43.8%	$13.35M	N/A	N/A	10	News Coverage
BLRX BioLineRx	0.8114 of 5 stars	$3.02 -1.1%	N/A	-37.6%	$13.18M	$1.18M	N/A	40	News Coverage Positive News
BIVI BioVie	0.4928 of 5 stars	$1.73 +9.2%	N/A	-77.6%	$13.01M	N/A	N/A	10	News Coverage Positive News Analyst Upgrade Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALBT) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalon GloboCare (ALBT) Competitors

ALBT vs. LNAI, COCP, BLRX, BIVI, and QNTM

How does Avalon GloboCare compare to Lunai Bioworks?

Summary

How does Avalon GloboCare compare to Cocrystal Pharma?

Summary

How does Avalon GloboCare compare to BioLineRx?

Summary

How does Avalon GloboCare compare to BioVie?

Summary

How does Avalon GloboCare compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalon GloboCare (ALBT) Competitors

ALBT vs. LNAI, COCP, BLRX, BIVI, and QNTM

How does Avalon GloboCare compare to Lunai Bioworks?

Which has more volatility and risk, LNAI or ALBT?

Which has preferable valuation and earnings, LNAI or ALBT?

Does the media prefer LNAI or ALBT?

Is LNAI or ALBT more profitable?

Do institutionals & insiders believe in LNAI or ALBT?

Do analysts prefer LNAI or ALBT?

Summary

How does Avalon GloboCare compare to Cocrystal Pharma?

Does the media favor ALBT or COCP?

Is ALBT or COCP more profitable?

Which has more risk & volatility, ALBT or COCP?

Which has higher valuation and earnings, ALBT or COCP?

Do institutionals and insiders hold more shares of ALBT or COCP?

Do analysts prefer ALBT or COCP?

Summary

How does Avalon GloboCare compare to BioLineRx?

Is ALBT or BLRX more profitable?

Which has preferable valuation & earnings, ALBT or BLRX?

Do insiders & institutionals believe in ALBT or BLRX?

Which has more volatility & risk, ALBT or BLRX?

Do analysts recommend ALBT or BLRX?

Does the media favor ALBT or BLRX?

Summary

How does Avalon GloboCare compare to BioVie?

Which has higher earnings and valuation, BIVI or ALBT?

Do institutionals and insiders have more ownership in BIVI or ALBT?

Does the media prefer BIVI or ALBT?

Which has more risk and volatility, BIVI or ALBT?

Is BIVI or ALBT more profitable?

Do analysts recommend BIVI or ALBT?

Summary

How does Avalon GloboCare compare to Quantum Biopharma?

Do insiders and institutionals hold more shares of ALBT or QNTM?

Which has higher valuation and earnings, ALBT or QNTM?

Does the media refer more to ALBT or QNTM?

Is ALBT or QNTM more profitable?

Do analysts prefer ALBT or QNTM?

Which has more risk & volatility, ALBT or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools